SCH 51344
(Synonyms: Ras/Rac Transformaton Blocker) 目录号 : GC17613An inhibitor of Ras/Rac transformation
Cas No.:171927-40-5
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kd: 49 nM
SCH 51344 is a potent MTH1 inhibitor.
MTH1, also known as NUDT1, is a nucleotide pool sanitizing enzyme. Loss-of-function of MTH1 impaired growth of KRAS tumour cells. RAS possessed interaction with multiple targets in the cell and regulates at least two signaling pathways, one controlling extracellular signal-regulated kinase (ERK) activation and the other regulating membrane ruffling formation. These two pathways could synergistically cause transformation.
In vitro: SCH 51344 inhibits Ras-accelerated malignant transformation and increases α-actin promoter-stimulated CAT activity in Ras-transformed cells. SCH 51344 has quite little effect on Ras-induced ERK and JNK activation. SCH 51344 inhibits Ras-accelerated membrane ruffling in REF-52 fibroblasts and abolishes anchorage-independent growth of Ras-mediated tumor cell lines. SCH 51344 also induces DNA damage in SW480 colon cancer cells [1,2].
SCH 51344 specifically inhibits membrane ruffling stimulated by activated forms of H-RAS, K-RAS, N-RAS, and RAC. Fibroblast cells treated with this compound had very little effect on activation of ERK and JUN kinase activities mediated by RAS. SCH 51344 was an effective inhibitor of the anchorage-independent growth of Rat-2 fibroblast cells (transformed by the three forms of oncogenic RAS and RAC V12). These facts suggest that a critical component inhibited by SCH 51344 existed in the membrane ruffling pathway downstream from RAC and indicated that this may be an effective approach targeting this pathway to inhibiting transformation by RAS and other oncogenes [1,2].
In vivo: So far, no study in vivo has been conducted.
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Walsh AB, Dhanasekaran M, Bar-Sagi D, Kumar CC. SCH 51344-induced reversal of RAS-transformation is accompanied by the specific inhibition of the RAS and RAC-dependent cell morphology pathway. Oncogene. 1997 Nov 20;15(21):2553-60.
[2]. Kumar CC, Ohashi K, Nagata K, Walsh A, Bar-Sagi D, Mizuno K. SCH 51344, an inhibitor of RAS/RAC-mediated cell morphology pathway. Ann N Y Acad Sci. 1999; 886: 122-31.
Cas No. | 171927-40-5 | SDF | |
别名 | Ras/Rac Transformaton Blocker | ||
化学名 | |||
Canonical SMILES | CC1=NN=C(N2)C1=C(NCCOCCO)C3=C2C=CC(OC)=C3 | ||
分子式 | C16H20N4O3 | 分子量 | 316.35 |
溶解度 | ≥ 31.6mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.1611 mL | 15.8053 mL | 31.6106 mL |
5 mM | 0.6322 mL | 3.1611 mL | 6.3221 mL |
10 mM | 0.3161 mL | 1.5805 mL | 3.1611 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。